BioCorRx director Kate Beebe DeVarney resigns

BioCorRx Inc. announces the resignation of director Kate Beebe DeVarney, Ph.D., effective August 31, 2026, stating there was no disagreement with the company.

Rhea-AI Filing Summary

BioCorRx Inc. (BICX) reports that Kate Beebe DeVarney, Ph.D. resigned from its board of directors, effective August 31, 2026. The company states that her resignation did not arise from any disagreement with BioCorRx Inc. or its subsidiary, BioCorRx Pharmaceuticals.

Filing Explained

Effective August 31, 2026, Kate Beebe DeVarney no longer serves on BioCorRx’s board, changing the company’s board composition.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Resignation effective date: August 31, 2026 Report signature date: September 4, 2026

2 metrics

Resignation effective date August 31, 2026 Effective date of Kate Beebe DeVarney, Ph.D.’s resignation from the board of directors

Report signature date September 4, 2026 Date the CEO signed the current report on behalf of BioCorRx Inc.

Key Terms

Emerging growth company, board of directors, subsidiary, Section 12(b)

4 terms

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

board of directors regulatory

"her position as a member of the board of directors"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

subsidiary financial

"nor BioCorRx Pharmaceuticals, a subsidiary of the Company"

A subsidiary is a company that is controlled or owned by a larger company, known as the parent company. Think of it like a branch or division of a bigger organization; it operates separately but is ultimately guided by the parent. For investors, understanding subsidiaries helps clarify how a larger company is structured and where its resources and risks are concentrated.

Section 12(b) regulatory

"Securities registered pursuant to Section 12(b) of the Act"

Section 12(b) of the U.S. Securities Exchange Act requires securities listed on a national stock exchange to be registered with the U.S. Securities and Exchange Commission (SEC) and to follow regular public reporting and disclosure rules. For investors, a 12(b) listing generally means more routine financial updates, regulatory oversight and easier buying and selling—like a storefront that must display its inventory and prices, making it simpler to inspect and trade the product.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What board change did BioCorRx Inc. (BICX) disclose in this 8-K?

BioCorRx Inc. disclosed that Kate Beebe DeVarney, Ph.D. resigned as a member of its board of directors, effective August 31, 2026. The company noted that her resignation was not due to any disagreement with BioCorRx Inc. or its subsidiary.

When was the director resignation at BioCorRx Inc. (BICX) effective?

The resignation of director Kate Beebe DeVarney, Ph.D. from the board of BioCorRx Inc. was effective on August 31, 2026, the same date she submitted her resignation to the company.

Did BioCorRx Inc. (BICX) report any disagreement related to the director’s resignation?

No. BioCorRx Inc. stated that Kate Beebe DeVarney’s resignation from the board did not arise from any disagreement with the company or with BioCorRx Pharmaceuticals, its subsidiary.

Which subsidiary of BioCorRx Inc. is mentioned in connection with the resignation?

The filing mentions BioCorRx Pharmaceuticals, a subsidiary of BioCorRx Inc., and clarifies that Kate Beebe DeVarney’s resignation did not result from any disagreement with this subsidiary or with the parent company.

Who signed the BioCorRx Inc. (BICX) 8-K reporting the director resignation?

The 8-K was signed on behalf of BioCorRx Inc. by Lourdes Felix, the company’s Chief Executive Officer, dated September 4, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 09:55 AM EDT Accepted by SEC EDGAR 09/04/2026 - 09:53 AM EDT Learn about SEC filing dates

0001443863false00014438632026-08-312026-08-31iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): August 31, 2026

BioCorRx Inc.

(Exact name of registrant as specified in its charter)

Nevada		000-54208		90-0967447
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

2390 East Orangewood Avenue, Suite 570

Anaheim, CA 92806

(Address of principal executive offices) (Zip Code)

(714) 462-4880

(Registrant’s telephone number, including area code)

________________________________________________

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignation of Director

On August 31, 2026, Kate Beebe DeVarney, Ph.D. submitted her resignation from her position as a member of the board of directors (the “Board”) of BioCorRx Inc.(the “Company”), effective August 31, 2026 (the “DeVarney Resignation”).

The DeVarney Resignation did not arise as a result of any disagreement with the Company nor BioCorRx Pharmaceuticals, a subsidiary of the Company.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	BioCorRx Inc.
Date: September 4, 2026	By:	/s/ Lourdes Felix
		Lourdes Felix
		Chief Executive Officer

3

Filing Exhibits & Attachments

5 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 4.9 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 12.9 KB
• EX-101 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE 898 B
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 8.1 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE 2.0 KB